MRK Stock Overview
Operates as a science and technology company in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for MRK from our risk checks.
Merck KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €115.30 |
| 52 Week High | €177.00 |
| 52 Week Low | €110.45 |
| Beta | 0.70 |
| 1 Month Change | -14.12% |
| 3 Month Change | -19.12% |
| 1 Year Change | -24.93% |
| 3 Year Change | -38.33% |
| 5 Year Change | 14.67% |
| Change since IPO | 643.44% |
Recent News & Updates
Is Merck KGaA (ETR:MRK) A Risky Investment?
Apr 09
Some May Be Optimistic About Merck KGaA's (ETR:MRK) Earnings
Mar 14Merck KGaA (ETR:MRK) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 09Recent updates
Is Merck KGaA (ETR:MRK) A Risky Investment?
Apr 09Some May Be Optimistic About Merck KGaA's (ETR:MRK) Earnings
Mar 14Merck KGaA (ETR:MRK) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 09Risks To Shareholder Returns Are Elevated At These Prices For Merck KGaA (ETR:MRK)
Feb 10We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt
Dec 16
AI-Driven Semiconductor Surge Powers Healthcare And Electronics To New Heights
Nov 24 Strong growth in semiconductor solutions and life sciences boosts Merck's Electronics and Process Solutions sectors, positively impacting future revenue and earnings.Some Shareholders Feeling Restless Over Merck KGaA's (ETR:MRK) P/E Ratio
Oct 18Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?
Sep 05Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly
Jul 24Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E
Jul 03Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price
May 22Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20
Apr 26Shareholder Returns
| MRK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.1% | -1.3% | -0.8% |
| 1Y | -24.9% | -24.3% | 2.3% |
Return vs Industry: MRK matched the German Pharmaceuticals industry which returned -25.3% over the past year.
Return vs Market: MRK underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.3% |
| 10% least volatile stocks in DE Market | 3.0% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1668 | 59,020 | Belen Garijo Lopez | www.merckgroup.com/en |
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company’s Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.
Merck KGaA Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | €50.13b |
| Earnings (TTM) | €2.78b |
| Revenue (TTM) | €21.16b |
18.1x
P/E Ratio2.4x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | €21.16b |
| Cost of Revenue | €8.63b |
| Gross Profit | €12.52b |
| Other Expenses | €9.75b |
| Earnings | €2.78b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 15, 2025
| Earnings per share (EPS) | 6.39 |
| Gross Margin | 59.20% |
| Net Profit Margin | 13.13% |
| Debt/Equity Ratio | 31.8% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
1.9%
Current Dividend Yield34%
Payout RatioDoes MRK pay a reliable dividends?
See MRK dividend history and benchmarks| Merck KGaA dividend dates | |
|---|---|
| Ex Dividend Date | Apr 28 2025 |
| Dividend Pay Date | Apr 30 2025 |
| Days until Ex dividend | 14 days |
| Days until Dividend pay date | 16 days |
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/11 10:28 |
| End of Day Share Price | 2025/04/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Merck KGaA is covered by 60 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Gerhard Schwarz | Baader Helvea Equity Research |
| Odile Rundquist | Baader Helvea Equity Research |